{"id":"rapid-acting-intramuscular-olanzapine","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Somnolence"},{"rate":"5-15%","effect":"Dry mouth"},{"rate":"5-15%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking these receptors, olanzapine reduces the activity of dopamine and serotonin in the brain, which helps to alleviate symptoms of psychosis and mania. This is thought to be due to the drug's ability to modulate the activity of these neurotransmitters and their receptors.","oneSentence":"Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:19.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"},{"name":"Treatment of bipolar disorder"}]},"trialDetails":[{"nctId":"NCT00970281","phase":"PHASE3","title":"A Study of Olanzapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Schizophrenia","enrollment":91},{"nctId":"NCT00640510","phase":"PHASE3","title":"A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-03","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT00316238","phase":"PHASE2","title":"A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-04","conditions":"Schizophrenia","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY170053","olanzapine","RAIM"],"phase":"phase_3","status":"active","brandName":"Rapid Acting Intramuscular Olanzapine","genericName":"Rapid Acting Intramuscular Olanzapine","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist. Used for Treatment of schizophrenia, Treatment of bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}